Search research articles
Contact Us
Filters
Showing results (101-110 of 118) with videos related to
Page
of 12
Sort By:
Clinical and Experimental Immunology
|
April 20, 2024
Obesity differs from diabetes mellitus in antibody and T-cell responses post-COVID-19 recovery
Mohammad Ali, Stephanie Longet, Isabel Neale, et al.
Nature Communications
|
August 18, 2021
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
Donal T Skelly, Adam C Harding, Javier Gilbert-Jaramillo, et al.
Journal of Virology
|
November 24, 2017
Differential Immunodominance Hierarchy of CD8<sup>+</sup> T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection
Emily Adland, Matilda Hill, Nora Lavandier, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 12, 2026
T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapy
Mohammed Altaf, Carla Nel, Timothy Tipoe, et al.
Nature
|
February 27, 2009
Adaptation of HIV-1 to human leukocyte antigen class I
Yuka Kawashima, Katja Pfafferott, John Frater, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 12, 2026
Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO Trial
Ming Jie Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
The Lancet. HIV
|
May 27, 2026
Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial
Ming J Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
The Lancet. HIV
|
March 20, 2019
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting
Boris Julg, Lynda Dee, Jintanat Ananworanich, et al.
The Lancet. Microbe
|
November 15, 2021
T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study
Adrienn Angyal, Stephanie Longet, Shona C Moore, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 5, 2022
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus
Sarah Fidler, Julie Fox, Timothy Tipoe, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 118) with videos related to
Sort By:
Page
of 12
Clinical and Experimental Immunology
|
April 20, 2024
Obesity differs from diabetes mellitus in antibody and T-cell responses post-COVID-19 recovery
Mohammad Ali, Stephanie Longet, Isabel Neale, et al.
Nature Communications
|
August 18, 2021
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
Donal T Skelly, Adam C Harding, Javier Gilbert-Jaramillo, et al.
Journal of Virology
|
November 24, 2017
Differential Immunodominance Hierarchy of CD8<sup>+</sup> T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection
Emily Adland, Matilda Hill, Nora Lavandier, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 12, 2026
T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapy
Mohammed Altaf, Carla Nel, Timothy Tipoe, et al.
Nature
|
February 27, 2009
Adaptation of HIV-1 to human leukocyte antigen class I
Yuka Kawashima, Katja Pfafferott, John Frater, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 12, 2026
Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO Trial
Ming Jie Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
The Lancet. HIV
|
May 27, 2026
Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial
Ming J Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
The Lancet. HIV
|
March 20, 2019
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting
Boris Julg, Lynda Dee, Jintanat Ananworanich, et al.
The Lancet. Microbe
|
November 15, 2021
T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study
Adrienn Angyal, Stephanie Longet, Shona C Moore, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 5, 2022
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus
Sarah Fidler, Julie Fox, Timothy Tipoe, et al.
Page
of 12